Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children. (2nd January 2020)

• Record Type: Journal Article
• Authors: Zhou, Hua; Lu, Yanming; Wu, Bin; Che, Datian
• Is Part Of: Journal of asthma. Volume 57:Number 1(2020)
• Page Start: 87
• Page End: 94
• Publication Date: 2020-01-02
• Subjects: Allergic asthma -- omalizumab -- cost-effectiveness -- quality-adjusted life-years -- Chinese; Asthma -- Periodicals; 616.238005
• DOI: 10.1080/02770903.2018.1544642
• Languages: English
• ISSNs: 0277-0903

Abstract

Abstract: Objective: The addition of omalizumab to standard therapy has proven to be efficacious in children with severe allergic asthma. The goal of this study was to assess the cost-effectiveness of adding omalizumab to standard treatment for asthma in Chinese pediatric patients. Methods: A Markov model was constructed to project the health and economic outcomes in pediatric patients with severe allergic asthma. Model inputs were obtained from the literature. Cost and quality-adjusted life-years (QALYs) were measured over a five-year time horizon. One-way and probabilistic sensitivity analyses were conducted. Results: For the base-case analysis, the addition of omalizumab to standard therapy yielded an incremental cost of $49, 047 for 0.232 incremental QALY, led to an incremental cost-effectiveness ratio of $211, 217/QALY. Sensitivity analyses were robust for these results. Conclusions: This study found that the addition of omalizumab is not a cost-effective strategy compared with standard therapy for children with severe allergic asthma in China due to its high cost.